Table 5. Serum uric acid* and hyperuricemia as a risk for incident CAD events in the subjects.
Crude | Model 1 | Model 2 | Model 3 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | HR | 95% CI | p-value | |
Total = 2142 | ||||||||||||
Hyperuricemia | 1.84 | 1.41–2.49 | < 0.001 | 1.81 | 1.40–2.42 | < 0.001 | 1.77 | 1.39–2.49 | < 0.001 | 1.73 | 1.27–2.31 | 0.001 |
Per SUA 1mg/dL | 1.19 | 1.12–1.26 | < 0.001 | 1.16 | 1.10–1.23 | < 0.001 | 1.13 | 1.11–1.24 | 0.001 | 1.11 | 1.05–1.20 | 0.001 |
Male sex = 1194 | ||||||||||||
Hyperuricemia | 1.81 | 1.31–2.61 | < 0.001 | 1.79 | 1.33–2.59 | < 0.001 | 1.75 | 1.30–2.4 | < 0.001 | 1.68 | 1.13–1.89 | 0.010 |
Per SUA 1mg/dL | 1.20 | 1.10–1.26 | < 0.001 | 1.18 | 1.09–1.25 | < 0.001 | 1.15 | 1.06–1.29 | < 0.001 | 1.12 | 1.03–1.24 | 0.038 |
Female sex = 948 | ||||||||||||
Hyperuricemia | 1.86 | 1.25–2.60 | 0.001 | 1.84 | 1.26–2.65 | 0.002 | 1.80 | 1.26–2.66 | 0.019 | 1.75 | 1.24–2.67 | 0.019 |
Per SUA 1mg/dL | 1.15 | 1.10–1.27 | < 0.001 | 1.14 | 1.10–1.28 | < 0.001 | 1.12 | 1.08–1.29 | < 0.001 | 1.10 | 1.05–1.30 | 0.001 |
*SUA indicated serum uric acid level of ending of study.
Model 1: Data adjusted for age, sex, smoking and drinking habits at the end of study.
Model 2: Data adjusted for baseline age, sex, smoking and drinking habits, baseline BMI, baseline systolic BP and diastolic BP at the end of study.
Model 3: Data adjusted for baseline age, sex, smoking and drinking habits, baseline BMI, baseline systolic BP and diastolic BP, and baseline eGFR, total-cholesterol, triglycerides, LDL and HDL at the end of study.
CAD = coronary artery disease; BMI = body mass index; BP = blood pressure; eGFR = estimated glomerular filtration rate; SUA = serum uric acid; LDL = low density lipoprotein; HDL = high density lipoprotein; HR = hazards ratio; CI = confidence interval.